电子QTL和多组组合显示PPIH是一种预后和免疫治疗生物标志物
Fenglin Lv1,2, Xinlu Zhang3, Yanmei Wu4
1Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China.
Frontiers in immunology
|September 2, 2025
概括
乙烯基异构酶H (PPIH) 被认为是一种潜在的泛癌生物标志物. 这种基因促进癌细胞的增殖和迁移,为癌症诊断和向治疗提供了新的途径.
科学领域:
- 癌症学
- 基因组学
- 生物信息学
背景情况:
- 恶性瘤对全球健康构成重大挑战.
- 识别新生物标志物对于推进癌症诊断和治疗至关重要.
研究的目的:
- 整合多组数据以识别癌症生物标志物候选者.
- 评估已识别的基因在瘤学的临床适用性.
主要方法:
- 使用表达量的特征位点和全基因组关联研究数据的孟德尔随机化.
- 多组生物信息学分析包括基因表达,基因组变化和瘤微环境 (TME) 关联.
- 单细胞转录组分析和体外验证实验.
主要成果:
- 已被确定为潜在的泛癌生物标志物.
- PPIH的表达异常,并且与多种癌症的预后相关.
- 在体外研究表明,PPIH促进肝细胞癌细胞的增殖,迁移和侵入.
结论:
- PPIH成为具有泛癌相关性的有希望的候选生物标志物.
- 这些发现支持PPIH在癌症诊断中的潜在临床价值.
- 这项研究为制定有针对性的治疗策略奠定了基础.
更多相关视频
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


